ArticleNuclear medicine and biology2019
Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours.
Article in Nuclear medicine and biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.EJNMMI research · 2024Article
- Combining PET and Compton imaging with edge-on CZT detectors for enhanced diagnostic capabilities.Advances in radiotherapy & nuclear medicine · 2024Article
- Influence of spill-over forPhysical and engineering sciences in medicine · 2024Article
- Intraoperative Gamma Cameras: A Review of Development in the Last Decade and Future Outlook.Journal of imaging · 2023Review
- Hybrid PET/Compton-camera imaging: an imager for the next generation.European physical journal plus · 2023Review
- Synthesis andBioconjugate chemistry · 2022Article
- Immunohistochemistry of Immune Cells and Cells Bound toBio-protocol · 2022Article
- Examining the Feasibility of Quantifying Receptor Availability Using Cross-Modality Paired-Agent Imaging.Molecular imaging and biology · 2022Article
- Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders-An Update.Cancers · 2020Review
- Imaging DNA Damage Repair In Vivo AfterJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Noninvasive quantification of target availability during therapy using paired-agent fluorescence tomography.Theranostics · 2020Article
- Comparison of Tumor Non-specific and PD-L1 Specific Imaging by Near-Infrared Fluorescence/Cerenkov Luminescence Dual-Modality In-situ Imaging.Molecular imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
While radiolabelled antibodies have found great utility as PET and SPECT imaging agents in oncological investigations, a notable shortcoming of these agents is their propensity to accumulate non-specifically within tumour tissue. The degree of this non-specific contribution to overall tumour uptake is highly variable and can ultimately lead to false conclusions. Therefore, in an effort to obtain a reliable measure of inter-individual differences in non-specific tumour uptake of radiolabelled antibodies, we demonstrate that the use of dual-isotope imaging overcomes this issue, enables true quantification of epitope expression levels, and allows non-invasive in vivo immunohistochemistry. The approach involves co-administration of (i) an antigen-targeting antibody labelled with zirconium-89 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.